Why it matters
Mitragynine accounts for roughly 60–70% of the alkaloid content in a dried kratom leaf. It is a partial agonist at the mu-opioid receptor and also acts on adrenergic, serotonergic, and dopaminergic systems — a polypharmacology that explains why low doses tend to feel stimulating and higher doses sedating. A January 2025 study published in Nature Chemistry by University of Florida researchers characterised mitragynine as a “biased agonist” at the mu-opioid receptor: it activates pain-relieving pathways while showing significantly weaker recruitment of beta-arrestin, the signalling pathway linked to respiratory depression in classical opioids.
In practice
In a kratom Certificate of Analysis, mitragynine concentration is usually reported as a percentage of total dry weight (typically 1–2% in commercial powder). Vendors who batch-test will publish that percentage on every batch label. Practically, that number lets the consumer compare relative potency across products and across vendors. It is not a substitute for dose-finding — variability in absorption and metabolism means two people taking the same milligrams of mitragynine can experience different effects.
Common confusion
Mitragynine is sometimes confused with its more potent metabolite 7-hydroxymitragynine (7-OH). The two are pharmacologically distinct: mitragynine is the parent compound, abundant in the leaf and milder per milligram; 7-OH is present in trace amounts in the raw leaf but is also generated when the body metabolises mitragynine. Concentrated 7-OH products marketed as “extracts” are not the same product class as leaf powder.
This glossary entry is editorial content reviewed against primary sources. It is not medical advice. See our Editorial Policy.